{{Rsnum
|rsid=5067
|Gene=NPPA
|Chromosome=1
|position=11845924
|Orientation=plus
|GMAF=0.1396
|Gene_s=NPPA,NPPA-AS1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 72.6 | 26.5 | 0.9
| HCB | 99.3 | 0.7 | 0.0
| JPT | 97.3 | 2.7 | 0.0
| YRI | 33.3 | 45.6 | 21.1
| ASW | 36.8 | 52.6 | 10.5
| CHB | 99.3 | 0.7 | 0.0
| CHD | 99.1 | 0.9 | 0.0
| GIH | 76.2 | 21.8 | 2.0
| LWK | 44.5 | 45.5 | 10.0
| MEX | 82.8 | 13.8 | 3.4
| MKK | 46.5 | 44.5 | 9.0
| TSI | 78.4 | 21.6 | 0.0
| HapMapRevision=28
}}
[[rs5067]] is a SNP in the natriuretic peptide precursor A [[NPPA]] gene.

In a study of ~500 [[asthma]] patients, [[rs5067]](G) were at reduced (50% or 76%) risk; the odds ratio in the first and second populations were 0.5 (CI: 0.29-0.84, p=0.009) and 0.24 (CI: 0.11-0.53, p<0.0001), respectively. The population-attributable risk for [[asthma]] in carriers of the [[rs5067]](G) allele was 23.3%.{{PMID|18294255}}

{{ neighbor
| rsid = 5065
| distance = 87
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}